Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

A randomised, controlled trial of bosentan in severe COPD

D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, M. Tamm
European Respiratory Journal 2008 32: 619-628; DOI: 10.1183/09031936.00011308
D. Stolz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Rasch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Linka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Di Valentino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Meyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Brutsche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Tamm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Pulmonary hypertension during exercise is common in severe chronic obstructive pulmonary disease (COPD). It was hypothesised that the use of the endothelin-receptor antagonist bosentan can improve cardiopulmonary haemodynamics during exercise, thus increasing exercise tolerance in patients with severe COPD.

In the present double-blind, placebo-controlled study, 30 patients with severe or very severe COPD were randomly assigned in a 2:1 ratio to receive either bosentan or placebo for 12 weeks. The primary end-point was change in the 6-min walking distance. Secondary end-points included changes in health-related quality of life, lung function, cardiac haemodynamics, maximal oxygen uptake and pulmonary perfusion patterns.

Compared with placebo, patients treated with bosentan during 12 weeks showed no significant improvement in exercise capacity as measured by the 6-min walking distance (mean±sd 331±123 versus 329±94 m). There was no change in lung function, pulmonary arterial pressure, maximal oxygen uptake or regional pulmonary perfusion pattern. In contrast, arterial oxygen pressure dropped, the alveolar–arterial gradient increased and quality of life deteriorated significantly in patients assigned bosentan.

The oral administration of the endothelin receptor antagonist bosentan not only failed to improve exercise capacity but also deteriorated hypoxaemia and functional status in severe chronic obstructive pulmonary disease patients without severe pulmonary hypertension at rest.

  • Endothelin-receptor antagonist
  • exercise capacity
  • pulmonary hypertension
  • treatment

Footnotes

  • For editorial comments see page 541.

  • © ERS Journals Ltd
View Full Text
PreviousNext
Back to top
View this article with LENS
Vol 32 Issue 3 Table of Contents
European Respiratory Journal: 32 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A randomised, controlled trial of bosentan in severe COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A randomised, controlled trial of bosentan in severe COPD
D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, M. Tamm
European Respiratory Journal Sep 2008, 32 (3) 619-628; DOI: 10.1183/09031936.00011308

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A randomised, controlled trial of bosentan in severe COPD
D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, M. Tamm
European Respiratory Journal Sep 2008, 32 (3) 619-628; DOI: 10.1183/09031936.00011308
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Support statement
    • Clinical trial
    • Statement of interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate
  • Calculating gambling odds and lung ages for smokers
  • Atrophy and hypertrophy signalling in the diaphragm of patients with COPD
Show more Original Articles: COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society